Search Results - "Ballard, Joshua A"

Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior by Rajagopalan, Ravi, Misialek, Shawn, Stevens, Sarah K, Myszka, David G, Brandhuber, Barbara J, Ballard, Joshua A, Andrews, Steven W, Seiwert, Scott D, Kossen, Karl

“…The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication. ITMN-191, a macrocyclic inhibitor of the NS3…”
Get full text

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor by Gomez, Eliana B., Ebata, Kevin, Randeria, Hetal S., Rosendahl, Mary S., Cedervall, E. Peder, Morales, Tony H., Hanson, Lauren M., Brown, Nicholas E., Gong, Xueqian, Stephens, Jennifer, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A., Abada, Paolo B., Ballard, Joshua A., Allerston, Charles K., Brandhuber, Barbara J.

“…•Pirtobrutinib is a potent, noncovalent (reversible), highly selective inhibitor of BTK and C481-mutant BTK.•Pirtobrutinib is efficacious in B-cell models…”
Get full text

Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor by Gomez, Eliana B, Ebata, Kevin, Randeria, Hetal S, Rosendahl, Mary S, Cedervall, Ernst Peder, Morales, Tony H, Hanson, Lauren M, Brown, Nicholas E, Gong, Xueqian, Stephens, Jennifer Rachelle, Wu, Wenjuan, Lippincott, Isabel, Ku, Karin S., Walgren, Richard A, Abada, Paolo B, Ballard, Joshua A, Allerston, Charles K, Brandhuber, Barbara J

“…Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell driven malignancies. However, approved covalent BTK…”
Get full text

Abstract 1464: Pre-clinical characterization of potent and selective next-generation RET inhibitors by Kolakowski, Gabrielle R., Anderson, Erin D., Ballard, Joshua A., Brandhuber, Barbara J., Condroski, Kevin R., Gomez, Eliana B., Irvin, Thomas C., Kumar, Manoj, Patel, Nisha A., Watson, Faith D., Andrews, Steven W.

“…Abstract In May 2020, selpercatinib became the first FDA-approved selective RET inhibitor, indicated for patients (pts) with RET fusion-positive NSCLC and…”
Get full text

Abstract P141: Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor by Ballard, Joshua A., Kercher, Timothy, Abraham, David, Brecht, Ryan, Brooks, Nathan A., Buckles, Thomas, Bume, Desta, Busha, David, Cedervall, Ernst Peder, Condroski, Kevin, Ebata, Kevin, Gharbi, Severine Isabelle, Hazlitt, Robert, Morales, Tony, Patel, Nisha, Podoll, Jessica, Urkalan, Kaveri, Villalain, Sandra Gomez, Walls, Shane, Watson, Faith, Yang, Peiyi, Brandhuber, Barbara J., Andrews, Steven W.

“…Abstract Alterations in the fibroblast growth factor receptors (FGFRs) have been identified as oncogenic drivers in many human cancers. Specifically,…”
Get full text

Abstract 2780: Unique pharmacodynamic properties conferred by differential binding to BTK, pirtobrutinib vs covalent inhibitors by Ballard, Joshua A., Ebata, Kevin, Randeria, Hetal S., Tinline, Garrett, Lee, Thomas, Hanson, Lauren M., Latham, John A., Cedervall, E. Peder, Chong, Jenny, Valle, Kyle B. Del, Collins, Bernard C., Morales, Tony H., Benedict, Thomas C., Schureck, Marc A., Bender, Ethan T., Mendoza, Christopher, Molina, David, Nakamoto, Meagan, Shiah, Hsiao-Chiao, Xu, Hao, Espada, Alfonso, Cano, Leticia, Allerston, Charles K., Schnier, Paul, Brandhuber, Barbara J.

“…Abstract Covalent Bruton tyrosine kinase inhibitors (cBTKi) have transformed the treatment of B cell malignancies. Despite the efficacy of cBTKi, treatment…”
Get full text

The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients by Hallin, Jill, Engstrom, Lars D, Hargis, Lauren, Calinisan, Andrew, Aranda, Ruth, Briere, David M, Sudhakar, Niranjan, Bowcut, Vickie, Baer, Brian R, Ballard, Joshua A, Burkard, Michael R, Fell, Jay B, Fischer, John P, Vigers, Guy P, Xue, Yaohua, Gatto, Sole, Fernandez-Banet, Julio, Pavlicek, Adam, Velastagui, Karen, Chao, Richard C, Barton, Jeremy, Pierobon, Mariaelena, Baldelli, Elisa, Patricoin, 3rd, Emanuel F, Cassidy, Douglas P, Marx, Matthew A, Rybkin, Igor I, Johnson, Melissa L, Ou, Sai-Hong Ignatius, Lito, Piro, Papadopoulos, Kyriakos P, Jänne, Pasi A, Olson, Peter, Christensen, James G

“…Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS inhibitor…”
Get more information